Fast Track designation highlights potential of INX-315 to address unmet need for patients with recurrent advanced/metastatic ...

Jakafi ® (ruxolitinib) net product revenues of $709 million in Q1'25 (+24% Y/Y); increasing full year 2025 Jakafi guidance to ...

Part 2a is designed to confirm the primary dose-of-interest with a target enrollment of approximately 30 patients at each of two dose levels: 400mg QD 5:2 and 300mg QD 5:2 (intermittent daily dosing ...

得到了较为稳定的酶活性。 我主要是来补充一个“失去了什么”的——失去了心脏的再生能力。 心肌梗死的预后问题是个困扰医生和病人很久的问题，这个事就是失去了心脏再生能力的结果，而这个结果就与恒温有关，甚至可以说是恒温的代价。

Bayer and Vividion Therapeutics to present latest research on their advancing oncology portfolio at AACR 2025 annual meeting: Berlin, Germany Wednesday, April 23, 2025, 10:00 Hrs ...